Boehringer Ingelheim
For Healthcare Professionals
GLYXAMBI Safety
GLYXAMBI Safety

GLYXAMBI

CVOT

GLYXAMBI® contains Empagliflozin and Linagliptin that has 3 PIVOTAL AND CONVINCING Cardiovascular Outcome Trials (CVOTs).1

empa-linag-logos.png

Empagliflozin in the EMPA-REG OUTCOME demonstrated Cardio-Renal Benefits and UNIQUELY demonstrated a significant 38% relative risk reduction in CV death.2,5

trial-outcome.png

Linagliptin in the CARMELINA and CAROLINA Trials demonstrated Cardio-Renal Safety.6

†EMPA-REG OUTCOME® trial: Primary outcome was reduction in CV events defined as composite endpoint of CV death, non-fatal MI, or non-fatal stroke. In patients with T2D and established CV disease, on top of standard of care.2

§Hard kidney outcomes (excluding albuminuria and including eGFR decline) with different definitions for substantial loss of kidney function.

Guidelines

T2D
References
  • 1.
    Glyxambi® Singapore Prescribing Information.
  • 2.
    Zinman B, Wanner C, Lachin J, et al. EMPA-REG OUTCOME® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
  • 3.
    Rosenstock J, Perkovic V, Johansen OE, et al; for the CARMELINA Investigators. E_ect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA. 2019;321(1):69-79.
  • 4.
    Rosenstock J, Kahn SE, Johansen OE. E_ect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155-1166.
  • 5.
    Wanner et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-334.
  • 6.
    Trajenta® Singapore Prescribing Information.